Clinical reference Biomarker Directory
Back to directory

Protein S-100B

Established

S100B serves two unrelated roles: helping triage head injury patients for CT imaging, and monitoring melanoma.

Also known as S100B S100 calcium-binding protein B
In plain language

This protein is released by brain cells after a head injury and can sometimes help doctors decide whether a CT scan is truly necessary. Confusingly, the same protein is also used as a completely unrelated tumor marker for melanoma skin cancer.

Biomarker & context

S100B is a calcium-binding protein released from brain astrocytes after neuronal injury, used as a biomarker to help assess traumatic brain injury severity, and separately, as an established melanoma tumor marker.

What it indicates

A normal S100B level drawn within a few hours of a head injury has a high negative predictive value for ruling out significant traumatic brain injury on CT imaging, supporting its use in some emergency department protocols to reduce unnecessary scanning. Separately and unrelated to its neurological use, elevated S100B in melanoma reflects tumor burden and is used for staging and monitoring.

Diagnosis & clinical testing

Measured via serum immunoassay; in head injury protocols, S100B is drawn within a defined early window (typically within 3-6 hours of injury) alongside clinical decision rules to determine whether CT imaging can safely be deferred.

Guiding treatment

In select low-risk head injury patients with a normal S100B and reassuring clinical exam, some emergency protocols allow avoiding a CT scan, reducing radiation exposure and healthcare costs; in melanoma, rising S100B during surveillance prompts further imaging workup for recurrence or metastasis.

Clinical significance

A normal early post-injury S100B has high negative predictive value for ruling out significant brain injury on CT.

References
  1. General emergency medicine and oncology reference literature on S100B in traumatic brain injury triage and melanoma monitoring.